Q-Med AB: Invitation to half-year report conference call

Business Wire,  July 14, 2008  

• E-mail
• Print
• Link

STOCKHOLM, Sweden -- Regulatory News:

Q-Med AB (STO:QMED):

Time: Thursday, July 24, 2008 at 11.30 a.m. CET.

To join the conference:  <

Swedish dial in number:  <
+ 46 (0)8 505 201 10
UK dial in number:       <
+44 (0)20 7162 0025
Q-Med participants:
Bengt Agerup, CEO
Alexander Kotsinas, CFO
Madelene Sandgren, Director Investor Relations
and Corporate Communications

The press release for Q-Med AB's half-year report will be released approximately 10.30 on July 24, 2008.

The slide presentation will be available at:
www.q-med.com/Investors/Presentations

A recorded version of the presentation will be available for seven working days on tel: Sweden +46 (0)8 505 203 33 or UK +44 (0)20 7031 4064, access code: 80 32 10.

Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate identity number 556258-6882. Tel: +46(0)18-474 90 00. Fax: +46(0)18-474 90 01. E-mail: info@q-med.com. Web: www.q-med.com.

In USA, Q-Med AB's affiliate is the wholly-owned subsidiary Q-Med Scandinavia, Inc.

Q-Med AB is a rapidly growing and profitable biotechnology/medical device company. The company develops, manufactures, markets, and sells primarily medical implants. The majority of the products are based on the company's patented technology, NASHA[TM], for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: Restylane[R] for filling lines and folds, contouring and creating volume in the face, Macrolane[TM] for body contouring, Durolane[TM] for the treatment of osteoarthritis of the hip and knee joints, Deflux[R] for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, and Solesta[TM] for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q Med today has just over 700 coworkers, with close to 500 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the OMX Nordic Exchange in Stockholm.

This information was brought to you by Cision http://newsroom.cision.com

COPYRIGHT 2008 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning